Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,444 questions · 1,518 findings · 135 reviews · Infectious Diseases

No studies found 135 · 8.9%GRADE not reported 150 · 9.9%Very low 350 · 23.1%Low 420 · 27.7%Moderate 321 · 21.1%High 142 · 9.4%

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications)

Complete clearance · people with scabies, 2 to 80 years of ageLocation: India, Pakistan

Oral ivermectin 200 μg/kg (1 to 3 doses) may leads to lower complete clearance ‐ week 1 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).

5 findings from 1 review
Show 2 more findings

Oral ivermectin 200 μg/kg (1 to 2 doses) vs topical permethrin 5% lotion (1 to 5 applications)

Complete clearance · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan

Oral ivermectin 200 μg/kg (1 to 2 doses) showed no clear difference in complete clearance ‐ week 1 ‐ IVER 1 dose versus PER on 5… compared with topical permethrin 5% lotion (1 to 5 applications) (low certainty).

4 findings from 1 review
Show 1 more finding

Oral ivermectin 200 μg/kg (1 to 2 doses) vs topical permethrin 5% lotion (1 to 5 applications)

Number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus PER on 5 consecutive nights · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan

It is very uncertain whether oral ivermectin 200 μg/kg (1 to 2 doses) changes number of participants with ≥ 1 AE ‐ week 2 ‐ IVER 2 doses versus… compared with topical permethrin 5% lotion (1 to 5 applications) (very low certainty).

1 finding from 1 review

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications)

Complete clearance · people with scabies, 5 to 80 years of ageLocation: Egypt, India

Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in complete clearance ‐ week 1 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (low certainty).

3 findings from 1 review

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical ivermectin 1% lotion/solution (1 to 3 applications)

Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: Egypt, India

It is very uncertain whether oral ivermectin 200 μg/kg (1 to 3 doses) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical ivermectin 1% lotion/solution (1 to 3 applications) (very low certainty).

1 finding from 1 review

Topical ivermectin vs topical permethrin 5% cream (1 to 3 applications)

Complete clearance · people with scabies, 5 to 80 years of ageLocation: India

Topical ivermectin 1% lotion (1 to 3 applications) showed no clear difference in complete clearance ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (moderate certainty).

1 finding from 1 review

Topical ivermectin vs topical permethrin 5% cream (1 to 3 applications)

Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 5 to 80 years of ageLocation: India

It is very uncertain whether topical ivermectin 1% lotion (1 to 3 applications) changes number of participants with ≥ 1 AE ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (very low certainty).

1 finding from 1 review

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications)

Number of participants with ≥ 1 AE ‐ week 4 · people with scabies, 2 to 80 years of ageLocation: India, Pakistan

Oral ivermectin 200 μg/kg (1 to 3 doses) showed no clear difference in number of participants with ≥ 1 AE ‐ week 4 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).

1 finding from 1 review

Intervention not reported

Death from all causes · HIV‐negative people with tuberculous pericarditis

The intervention showed no clear difference in death from all causes (low certainty).

1 finding from 1 review

Intervention not reported

Cancer · HIV‐positive people with tuberculous pericarditis. Most patients (80%) not on antiretroviral drugs

It is very uncertain whether the intervention changes cancer (very low certainty).

1 finding from 1 review

Intervention not reported

Death from pericarditis · HIV‐negative people with tuberculous pericarditis

The intervention probably leads to lower death from pericarditis (moderate certainty).

1 finding from 1 review

Intervention not reported

Constrictive pericarditis · HIV‐negative people with tuberculous pericarditis

It is very uncertain whether the intervention changes constrictive pericarditis (very low certainty).

1 finding from 1 review

Intervention not reported

Repeat pericardiocentesis · HIV‐negative people with tuberculous pericarditis

The intervention showed no clear difference in repeat pericardiocentesis (low certainty).

1 finding from 1 review

Intervention not reported

Cancer · HIV‐negative people with tuberculous pericarditis

It is very uncertain whether the intervention changes cancer (very low certainty).

1 finding from 1 review